Fibromyalgia statistics: four million U.S. adults and the multi-year wait for a diagnosis

She was 41 when she stopped trusting her own body. Pain moved. Shoulders one week, hips the next, then a diffuse ache that never quite settled. Sleep never restored her. She had clean labs, normal imaging, and a stack of notes that said "stress," "anxiety," or "possible early arthritis" without a plan. Three years into that pattern she sat in my exam room with a list of specialties she had already seen, and asked whether I thought any of it was real.

It was real. Fibromyalgia is a clinical syndrome of widespread pain with unrefreshing sleep, fatigue and cognitive fog. It sits at the edge of several fields at once, including rheumatology and primary care, with neurology and gynecology often involved. There is no blood test that seals the diagnosis. That absence is exactly why the numbers matter. That is also why they are so often misquoted.

This article gathers the figures a reporter or clinician can lift with a source named beside them: U.S. prevalence, the female share of the burden, how long people wait for a name, the dense overlap with ME/CFS and endometriosis, what the disability data actually show, and how the diagnostic criteria themselves have changed since 1990.

Group	Prevalence
All U.S. adults	1.75%
Women	2.38%
Men	1.06%
Ages 18-29	0.76%
Ages 50-59	2.41%

Source: Walitt B, et al. PLoS ONE, 2015. Surrogate 2010 ACR criteria applied to 2012 NHIS; weighted sample representing 225.7 million U.S. adults.

How common fibromyalgia is, and who has it

Start with the number the CDC still cites: fibromyalgia affects about 4 million U.S. adults, or about 2% of the adult population. The agency also states that women are twice as likely to have it as men, and that risk rises with age, with most people diagnosed in middle age.

Population surveys that apply modern criteria land in a similar band. Walitt and colleagues, writing in PLoS ONE in 2015, applied surrogate 2010 American College of Rheumatology (ACR) criteria to the 2012 National Health Interview Survey. They estimated that 1.75% of U.S. adults, about 3.94 million people, met criteria. Prevalence was 2.38% in women and 1.06% in men (odds ratio 2.28). Rates climbed from 0.76% at ages 18-29 to 2.41% at ages 50-59 and then leveled.

Those two estimates are not in conflict. Prevalence moves when the case definition moves. Vincent and colleagues, using the Rochester Epidemiology Project in Olmsted County, Minnesota, illustrated that gap in Arthritis Care & Research in 2013: the age- and sex-adjusted prevalence of diagnosed fibromyalgia in clinical records was 1.1%, while a mail survey using research criteria estimated 6.4%. Many people who meet research criteria never receive the diagnosis in ordinary care, and some who receive a clinical label may not meet survey criteria.

An older U.S. population study by Wolfe and colleagues in 1995 put prevalence at 2.0% overall, 3.4% in women, and 0.5% in men under the 1990 tender-point criteria. That is a steeper female-to-male ratio than modern surveys show. Clinic cohorts skew further still: Salaffi's 2024 registry analysis of 616 patients was 92.2% female. Part of that is biology; part is who gets believed and coded. NIAMS, reviewing the condition in May 2024, notes the same pattern without inventing a single global percentage: more women than men, usual onset in middle age, and higher odds when rheumatic disease, mood disorders, or other chronic pain conditions are already present.

Method	Age- and sex-adjusted prevalence
Clinical diagnosis in medical records	1.1%
Mail survey using research criteria	6.4%

Source: Vincent A, et al. Arthritis Care & Research, 2013. Rochester Epidemiology Project, Olmsted County, Minnesota.

How long diagnosis takes, and why it matters

If prevalence is the first number people ask for, diagnostic delay is the one patients recognize in their own timelines. It is personal. It shows up in calendar years, not percentages.

In a 2024 cohort from the Italian Fibromyalgia Registry, Salaffi and colleagues analyzed 616 adults diagnosed under the 2016 ACR criteria. Mean disease duration was 6.46 years. Mean time from symptom onset to diagnosis was 3.45 years (standard deviation 2.39). Only 169 patients were diagnosed within one year; 320 waited more than one year but less than five; and 127 waited more than five years. Men and women did not differ significantly in delay. Median Polysymptomatic Distress Scale scores rose with that wait: 10.00 early, 16.00 late, 23.00 very late. The other clinimetric indices worsened in the same direction. Correlation is not proof that delay causes severity, but the gradient is steep enough that "wait and see" is not a neutral strategy.

An earlier primary-care analysis from Israel put the wait even longer. Gendelman and colleagues studied 2,369 patients with confirmed fibromyalgia and reported a mean total time to diagnosis of 6.42 years, including 3.75 years under the same primary physician who eventually made the diagnosis. Younger patients, higher comorbidity, and older physician age tracked with longer delays. That study is not a U.S. sample, but it is one of the cleanest real-world estimates of how long the process can take when care sits mostly in primary care.

The NHIS analysis adds a different kind of delay: failure to name the syndrome at all. Among people who met study criteria, 73% reported a physician diagnosis other than fibromyalgia. Only 27% said a clinician had ever told them they had the condition. Many carried labels such as rheumatoid arthritis, low back pain, or undifferentiated "arthritis." That shapes treatment offers, workplace accommodations, and whether a patient is believed the next time pain flares. In clinic, the pattern often looks like years of regional pain, primary insomnia, freestanding anxiety or depression, and separately tracked pelvic pain. Each is real, and none is synthesized. Our coverage of sleep disorders in women and anxiety and depression statistics describes two pathways that frequently run alongside this one.

Diagnostic timing	Patients (n)	Median PDS score
Early (≤1 year)	169	10.00
Late (>1 to <5 years)	320	16.00
Very late (>5 years)	127	23.00

Source: Salaffi F, et al. Clinical and Experimental Rheumatology, 2024. Mean time to diagnosis overall: 3.45 years (SD 2.39); n = 616, 92.2% female.

Overlap with ME/CFS and endometriosis

Fibromyalgia rarely travels alone. The cleanest recent U.S. data on chronic overlapping pain conditions come from the CDC-supported Multi-site Clinical Assessment of ME/CFS (MCAM) study, analyzed by Fall and colleagues in BMC Neurology in 2024. Among 595 people with ME/CFS and 328 healthy controls, 76% of ME/CFS participants had at least one chronic overlapping pain condition, compared with 17.4% of controls. Fibromyalgia was the second most common after chronic migraine/headache: 45.0% of ME/CFS participants met fibromyalgia criteria. Chronic low back pain (33.1%) and irritable bowel syndrome (31.6%) followed. Nearly all individual overlapping conditions were more frequent in women than in men.

That 45% figure is a specialty-clinic number, not a population rate. It still matters: when a patient already carries an ME/CFS diagnosis, widespread pain changes pain treatment, activity pacing, and what recovery can look like. Post-viral illness has made the intersection harder to ignore. Our review of long COVID statistics in women sits in the same family of multi-system syndromes that share fatigue, cognitive fog, and pain amplification.

Endometriosis is the other women's-health overlap with a named large-database source. Greenbaum and colleagues, using an Israeli health-plan population of 781,571 adult women, identified 6,647 with endometriosis (8.5 per 1,000) and 25,425 with fibromyalgia (32 per 1,000). Four hundred one women carried both diagnoses. Fibromyalgia prevalence among women with endometriosis was 6%. That is roughly double many general-population female rates. Women with both conditions also showed elevated autoimmune comorbidity and higher use of antidepressants and anxiety/depression care. The data are weaker than a casual reader might hope: both conditions are underdiagnosed, and codes capture care-seeking rather than true biologic co-occurrence. The direction is still consistent. For the broader epidemiology, see our endometriosis diagnosis and treatment statistics and autoimmune disease statistics. Migraine is another frequent companion; our migraine in women statistics cover that piece of the chronic overlapping pain cluster.

Work disability and health-care use

The survey data support a precise claim. A large share of people who meet criteria cannot work. Disability awards are far more common than in the general adult population.

In the 2012 NHIS analysis by Walitt and colleagues, among adults under age 65 who met fibromyalgia criteria, 55.8% reported being unable to work now because of health, compared with 5.8% without fibromyalgia. Half (50.5%) had ever filed a Social Security disability application, versus 5.8% without. Disability payments in the prior year went to 30.2% versus 2.8%. Sex differences inside the fibromyalgia group were large for work inability (71.3% of men vs 41.3% of women under 65) but not for recent disability payments (32.4% of men vs 28.1% of women).

Health-care use tracks the same severity. People meeting criteria averaged 8.69 medical visits a year versus 3.84 without. That is about 4.85 extra visits. Hospitalization in the prior year was 17.7% versus 8.8%. Specialist visits were roughly doubled (49.7% vs 25.2%). The CDC states that adults with fibromyalgia are twice as likely to be hospitalized and more than three times more likely to have major depression.

An older multicenter clinic study by Wolfe and colleagues (1997) still gets cited in disability debates. Among 1,604 patients in six rheumatology centers, more than 16% reported Social Security disability payments (center range 6.3% to 35.7%), compared with 2.2% of the U.S. population then. Counting any disability payment raised the share to 26.5%. At the same time, 64% said they could work all or most days. Center variation was enormous: referral patterns and local adjudication culture shape these numbers almost as much as pain scores. None of these datasets is a modern Social Security Administration case-processing report for fibromyalgia alone. What they establish is large work-capacity loss and elevated disability claims relative to adults without the syndrome.

Outcome	With fibromyalgia	Without fibromyalgia
Unable to work because of health	55.8%	5.8%
Ever filed Social Security disability application	50.5%	5.8%
Received disability payments in past year	30.2%	2.8%
Mean medical visits in past year (all ages)	8.69	3.84

Source: Walitt B, et al. PLoS ONE, 2015. Work and disability rows restricted to adults under 65; visit counts are population estimates from the same analysis.

How diagnostic criteria have changed

Why do prevalence estimates swing? The case definition. It has been rewritten three major times. Each rewrite changes who counts.

In 1990, the ACR published classification criteria from a multicenter study of 558 patients (293 with fibromyalgia, 265 controls). Widespread pain plus tenderness at 11 or more of 18 tender-point sites yielded 88.4% sensitivity and 81.1% specificity. That exam became the public face of fibromyalgia for two decades and favored a musculoskeletal-tenderness phenotype more often recognized in women.

In 2010, and in a 2011 self-report modification for surveys, the ACR replaced tender points with a Widespread Pain Index and a Symptom Severity Scale scoring fatigue, unrefreshing sleep, and cognitive symptoms. The 2016 revision by Wolfe and colleagues required generalized pain in at least four of five body regions, symptoms for at least three months, and sufficient index scores. Against 1990 and clinical criteria, the 2010/2011 criteria had median sensitivity of 86% and specificity of 90%. The 2016 update added the generalized-pain rule to reduce misclassification of regional pain syndromes.

Each change shifts epidemiology. Symptom-based criteria capture more men and more multi-system cases than classic tender-point exams. Population surveys find roughly a 2-to-1 female excess; specialty clinics still see cohorts that are more than 90% female. Both can be true: the biology is sex-skewed, and the path into specialty care is more skewed still. There is no laboratory confirmation. NIAMS is explicit that diagnosis rests on history and exam, with exclusion of better explanations. That leaves room for underdiagnosis (the 73% of criteria-positive adults without a clinical label) and for overdiagnosis when labels outrun research criteria. Fibromyalgia is real and common, yet still poorly operationalized in everyday practice.

For patients tracking symptom timing (pain flares around menses, irregular cycles under chronic illness) tools such as our period calculator and cycle length calculator can organize a history primary care and gynecology both need. They do not diagnose fibromyalgia. They make temporal patterns of pain and bleeding easier to see.

Taken together, the statistics support a modest and useful claim. About one in fifty U.S. adults lives with this syndrome by public-health estimates. Women carry roughly twice the prevalence of men in population data and a much higher share of clinic diagnoses. Diagnosis still takes years for many people, and most who meet research criteria never receive the clinical name. Overlap with ME/CFS and endometriosis is common enough that siloed care misses the pattern. Work disability is not rare. The criteria have improved, but they remain clinical judgments without a confirmatory test, which is why primary sources, not secondary web pages, should be the ones you quote.

Frequently asked questions about fibromyalgia statistics

How common is fibromyalgia in the United States?

The CDC estimates that fibromyalgia affects about 4 million U.S. adults, or roughly 2% of the adult population. A 2015 analysis of the 2012 National Health Interview Survey using surrogate 2010 ACR criteria found 1.75% of adults, about 3.94 million people, met symptom criteria. Survey methods and clinical coding produce different numbers, but both land near 2%.

Is fibromyalgia more common in women?

Yes. The CDC states that women are twice as likely to have fibromyalgia as men. In the 2012 NHIS analysis, prevalence was 2.38% in women versus 1.06% in men (odds ratio 2.28). Clinic and registry cohorts are often more than 90% female, a steeper skew than population surveys, which suggests both biology and referral patterns are at work.

How long does it take to get a fibromyalgia diagnosis?

It varies by country and care setting. In a 2024 Italian registry study of 616 patients, mean time from symptoms to diagnosis was 3.45 years. A 2018 primary-care analysis from Israel reported a mean of 6.42 years. Longer delays tracked with worse severity scores in the Italian cohort. Many people who meet research criteria never receive a clinical diagnosis at all.

How often does fibromyalgia overlap with ME/CFS?

Very often in specialty samples. In the Multi-site Clinical Assessment of ME/CFS analysis published in 2024, 45.0% of people with ME/CFS also met fibromyalgia criteria, and 76% had at least one chronic overlapping pain condition versus 17.4% of healthy controls. Those figures come from specialty clinics, not a random population sample.

Is fibromyalgia linked to endometriosis?

Yes, in large database studies. Greenbaum and colleagues found fibromyalgia in 6% of women with endometriosis in an Israeli health-plan population of more than 780,000 adult women, with 401 women carrying both diagnoses. Co-occurrence was associated with higher autoimmune disease burden and greater use of mental-health care. Underdiagnosis of both conditions means true overlap may be higher.

Does fibromyalgia cause work disability?

It is strongly associated with reduced work capacity. Among working-age adults meeting NHIS fibromyalgia criteria, 55.8% reported being unable to work because of health, versus 5.8% without fibromyalgia, and 30.2% received disability payments in the prior year versus 2.8%. An older clinic study found more than 16% on Social Security disability, while 64% still reported being able to work most days.